Off the wire
• China makes largest-ever haul of pangolin scales  • Foreign exchange rates in Singapore  • Feature: Displaced Syrians happy to learn victory of Aleppo  • Yearender: Chinese sports 2016 year in review  • 2nd Ld-Writethru: China's industrial profit growth accelerates to 14.5 pct in November  • Roundup: S.Korean presidential hopeful raises doubt about THAAD capability, aim behind deployment  • 7 Vietnamese proposed death penalties for sale of 5,000 heroin cakes  • 2nd LD: China issues white paper on space activities  • Chinese football investments move European leagues forward: experts  • "Rogue One: A Star Wars Story" tops North American box office for second time  
You are here: 　 Home

Chinese HCV drug expected for commercial use

Xinhua, December 27, 2016 Adjust font size:

China's first oral antiviral drug, dubbed ASC08, for treating Hepatitis C virus (HCV) is going through approval procedure for general use with the food and drug authority.

The drug requires a 12 week course of treatment. Clinical tests show it can cure 90 percent of HCV patients, said chief of the development team, Wu Jinzi, who set up Ascletis Pharmaceutical in 2014 in east China's Hangzhou City for pharmaceutical development and production.

China has more than 8.5 million people with HCV. The Hepatitis C can develop into fibrosis and cirrhosis of the liver and even liver cancer.

Wu said the new drug can provide an affordable and effective cure for HCV.

An HCV drug sold by American drug maker Gilead costs 84,000 U.S. dollars for a course of therapy, or around 1,000 dollars per day, far beyond the means of almost all sufferers.

Wu said the price for ASC08 has not yet been set, but it will be much cheaper than the American drug. Endi